The Promising Role of Microbiome-Based Drugs for the Treatment and Prevention of Recurrent Clostridioides Difficile | PTCE Pharmacy Connect

Educational Objectives Discuss the role of disruptions in the gut microbiome in the development of Clostridioides difficile infection (CDI) and recurrent CDIs Review the efficacy, safety, and role of fecal microbiota transplantation and emerging microbiome-based drugs for treatment of CDIs and rCDIs Faculty: Kevin W. Garey, PharmD, MS Professor and Chair University of Houston College of Pharmacy  Houston, Texas Kevin W. Garey, PharmD, MS, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Summit, Acurx, and Parakek Pharmaceuticals, and Seres Therapeutics Consultant: Ferring Pharmaceuticals Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-048-H01-P. The activity is available for CE credit through January 31, 2023. This activity is supported by a medical education grant from Ferring Pharmaceuticals. Participants can claim credit for this CE activity by following the link below: https://www.pharmacytimes.org/courses/the-promising-role-of-microbiome-based-drugs-for-the-treatment-and-prevention-of-recurrent-clostridioides-difficile Learn more about your ad choices. Visit megaphone.fm/adchoices